Abstract
Recent guidelines from multiple organizations stress screening initiation no earlier than the age of 21 years and increased screening intervals for women aged 21 to 29 years. Primary prevention with human papillomavirus vaccination has the potential to significantly affect the development of high-grade cervical lesions, including cancer, and will likely affect screening guidelines in the future.
Copyright © 2013 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Child
-
Colposcopy / adverse effects
-
Consensus
-
Developing Countries / statistics & numerical data
-
Female
-
Humans
-
Mass Screening / methods*
-
Mass Screening / trends
-
Papanicolaou Test
-
Papillomavirus Infections / diagnosis
-
Papillomavirus Infections / prevention & control
-
Papillomavirus Infections / transmission
-
Papillomavirus Vaccines
-
Practice Guidelines as Topic
-
Sexually Transmitted Diseases
-
Uterine Cervical Dysplasia / epidemiology
-
Uterine Cervical Dysplasia / pathology
-
Uterine Cervical Dysplasia / virology
-
Uterine Cervical Neoplasms / pathology*
-
Uterine Cervical Neoplasms / prevention & control*
-
Uterine Cervical Neoplasms / virology
-
Vaginal Smears
-
Young Adult